Name in SEC filings: Dyne Therapeutics, Inc.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| zeleciment rostudirsen (DYNE-251) | target date (company stated) | PDUFA | January 21, 2027 | SEC filing · |
| z-basivarsen | /data readout | Other | 2027 | EX-99.1 · |
Source: ORION, orionbiotechai.com/company/DYN, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/DYN
zeleciment rostudirsen (DYNE-251) · PDUFA target date (company stated) · January 21, 2027
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Duchenne muscular dystrophy amenable to exon 51 skipping
PDUFA target date (company stated)January 21, 2027
Stage: PDUFASEC filing · “PDUFA target action date”
Public float: $948,000,000 · as of · SEC filing
PDUFA target action date set for January 21, 2027
SEC filing · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-01)
Topline/data readoutQ1 2027
Stage: OtherSEC filing · “Phase 1/2”
Public float: $948,000,000 · as of · SEC filing
Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC)
EX-99.1 · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-03)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| z-basivarsenClinical results | Q1 2027“Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC)” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| z-basivarsenClinical results | Q1 2027“Topline data from the ACHIEVE REC are planned for Q1 2027” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| zeleciment rostudirsen (DYNE-251)FDA decision | January 21, 2027“PDUFA target action date set for January 21, 2027” Filed · SEC original | Period not started The stated period has not started yet, so there is nothing to compare. |
| zeleciment rostudirsen (DYNE-251)FDA decision | January 21, 2027“Prescription Drug User Fee Act (PDUFA) target action date set for January 21, 2027” Filed · SEC original | Period not started The stated period has not started yet, so there is nothing to compare. |
| zeleciment rostudirsen (DYNE-251)FDA decision | January 21, 2027“Prescription Drug User Fee Act, or PDUFA, target action date of January 21, 2027” Filed · SEC original | Period not started The stated period has not started yet, so there is nothing to compare. |
| zeleciment rostudirsen (DYNE-251)FDA decision | January 21, 2027“Prescription Drug User Fee Act target action date of January 21, 2027” Filed · SEC original | Period not started The stated period has not started yet, so there is nothing to compare. |
| z-basivarsenClinical results | Q1 2027“topline data planned for Q1 2027” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| z-basivarsenClinical results | Q1 2027“data from the ACHIEVE REC are planned for Q1 2027” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for DYN. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See DYN in the calendar · Review labels and methodology